HF-125, a first-in-class computer-modeled novel inhibitor of Tribbles 2, for therapy of enzalutamide resistant, neuroendocrine prostate cancer
. Based on these findings, HF-125 emerges as a promising novel agent for development of a new therapeutic strategy for ERPC-NE/NEPC types of aggressive prostate cancer.
Authors
- J. J. Ghosh (ORCID: https://orcid.org/0000-0002-3219-8416)
- Sougata Ghosh Chowdhury
- Jitender Monga (ORCID: https://orcid.org/0000-0001-5492-8881)
- Craig Rogers
- Steve Brown
- Pritam Biswas
Institutions
- Henry Ford Health System (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-04-30
- DOI
- https://doi.org/10.64898/2026.04.27.720588
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00